Co-Diagnostics, Inc. Class Action Lawsuit
- Company Name
- Co-Diagnostics, Inc.
- Stock Symbol
- Class Period
- February 25, 2020 to May 15, 2020
- Motion Deadline
- August 17, 2020
- District of Utah
The Co-Diagnostics, Inc. class action lawsuit charges Co-Diagnostics and certain of its officers and directors with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Co-Diagnostics securities between February 25, 2020 and May 15, 2020 (the “Class Period”). The Co-Diagnostics class action lawsuit was commenced on June 15, 2020 in the District of Utah and is captioned Gelt Trading, Ltd. v. Co-Diagnostics, Inc., No. 20-cv-00368.
According to the Co-Diagnostics class action lawsuit, due to Co-Diagnostics’ purported expertise in DNA-based testing, the world’s recent need for accurate Covid-19 testing presented Co-Diagnostics with a business opportunity. However, as the Co-Diagnostics class action lawsuit alleges, defendants made continual, knowing, and willful misstatements about their main product, a Covid-19 diagnostic test, to pump of the price of Co-Diagnostics’ stock while the officers and directors exercised low priced options and dumped their stock into the market. For example, defendants allegedly made false statements to the market regarding the accuracy of Co-Diagnostics’ Covid-19 tests, stating that the tests were 100% accurate – a claim that appeared to set Co-Diagnostics apart from its competitors.
On May 14, 2020, news outlets reported that Co-Diagnostics was reticent to participate in U.S.-based testing to verify its accuracy claims. As public reports casting doubt on Co-Diagnostics’ claims of 100% accuracy began to circulate, the stock declined, closing at $22.13 per share that day.
Later that evening, in response to other drug companies’ widely reported struggles with test accuracy, financial news services began reporting that the U.S. Food and Drug Administration (“FDA”) had announced that no Covid-19 test was 100% accurate. The FDA’s announcement undermined Co-Diagnostics’ claims about its tests’ 100% accuracy. On this news, Co-Diagnostics’ stock price fell again the following trading day – further damaging investors.
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Co-Diagnostics securities during the Class Period to seek appointment as lead plaintiff in the Co-Diagnostics class action lawsuit. A lead plaintiff will act on behalf of all other class members in directing the Co-Diagnostics class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Co-Diagnostics class action lawsuit. An investor’s ability to share in any potential future recovery of the Co-Diagnostics class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Co-Diagnostics class action lawsuit or have questions concerning your rights regarding the Co-Diagnostics class action lawsuit, please provide your information here or contact counsel, J.C. Sanchez of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at email@example.com. Lead plaintiff motions for the Co-Diagnostics class action lawsuit must be filed with the court no later than August 17, 2020.
Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities class action litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations and the media as leading lawyers in the industry.